The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Researchers from Gedeon Richter plc have reported the discovery of novel dual vasopressin V1A/V2 antagonist drug candidates for the potential treatment of hyponatremia.

In the Jan. 1, 2025, issue of Nature, researchers from the Allen Institute presented a map of areas and cell types where ...

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune ...

Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

The BioWorld Insider podcast is a monthly dive into the business and science of drug development. Conversations with CEOs and ...

Cyclarity Therapeutics Inc. has obtained regulatory approval to begin a first-in-human trial of UDP-003 . Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing ...

Aromatase inhibitors (AI) are among the most widely used therapies in the treatment of breast tumors expressing estrogen ...